Accumetrics enrolls 1,000th patient in CV test trial

US firm Accumetrics has enrolled its 1,000th patient into its landmark GRAVITAS trial, designed to demonstrate the value of providing  clinicians with actionable information for patients who are poor  responders to Plavix (clopidogrel).

The multicenter, placebo-controlled study will determine whether  tailored antiplatelet therapy for poor responders, identified based on  the results of the company's VerifyNow P2Y12 Test, reduces major  cardiovascular adverse events  following percutaneous coronary  intervention. Currently, the trial is being conducted at more than 70  sites in the USA and Canada, with a total enrollment goal of  approximately 2,800 patients.

"This is a very significant milestone for Accumetrics as it brings us  ever-closer to our goal of demonstrating the value of the VerifyNow  System. By identifying and adjusting therapy for patients that are not  responding adequately to standard doses of clopidogrel, GRAVITAS will be  the largest multicenter clinical trial that links testing with  personalized medicine and improved outcomes. We believe that the  VerifyNow System will be seen as an integral tool in ensuring that  patients receive not only the most appropriate antiplatelet therapy, but  also the adequate dose," said Jeff Dahlen, vice president of clinical  and regulatory affairs at Accumetrics.